NeoGenomics, Inc. (NEO) is a publicly traded Healthcare sector company. As of July 9, 2026, NEO trades at $14.88 with a market cap of $1.89B and a P/E ratio of 0.00. NEO moved +3.86% today. Year to date, NEO is +21.09%; over the trailing twelve months it is +91.14%. Its 52-week range spans $4.72 to $19.12. Analyst consensus is buy with an average price target of $14.93. Rallies surfaces NEO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
NeoGenomics Debuts FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer: NeoGenomics launched the first FDA-approved PTEN immunohistochemistry companion diagnostic for prostate cancer, enabling precise detection of PTEN loss in tumor samples. The assay complements its oncology testing portfolio and targets a sizable prostate cancer patient base, potentially driving incremental lab revenue and strengthening diagnostics offerings.
| Metric | Value |
|---|---|
| Price | $14.88 |
| Market Cap | $1.89B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $19.12 |
| 52-Week Low | $4.72 |
| Volume | 232.64K |
| Avg Volume | 0 |
| Revenue (TTM) | $727.33M |
| Net Income | $-108.03M |
| Gross Margin | 43.21% |
10 analysts cover NEO: 0 strong buy, 7 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $14.93.